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 2 
Abstract 17 
A full-length infectious cDNA clone of the genome of a foot-and-mouth disease virus isolated 18 
from the 2010 epidemic in Japan was constructed and designated pSVL-f02. Transfection of Cos-7 19 
or IBRS-2 cells with this clone allowed the recovery of infectious virus. The recovered virus had the 20 
same in vitro characterization as the parental virus with regard to antigenicity in neutralization and 21 
indirect immunofluorescence tests, plaque size and one-step growth. Pigs were experimentally 22 
infected with the parental virus or the recombinant virus recovered from pSVL-f02 transfected cells. 23 
There were no significant differences in clinical signs or antibody responses between the two groups, 24 
and virus isolation and viral RNA detection from clinical samples were similar. Virus recovered from 25 
transfected cells therefore retained the in vitro characteristics and the in vivo pathogenicity of their 26 
parental strain. This cDNA clone should be a valuable tool to analyze determinants of pathogenicity 27 
and mechanisms of virus replication, and to develop genetically engineered vaccines against 28 
foot-and-mouth disease virus. 29 
 30 
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    Foot-and-mouth disease (FMD) is the most contagious disease of cloven-hoofed animals. 32 
Outbreaks of FMD cause enormous economic damage to the livestock industry by reducing 33 
livestock productivity and interrupting international trade of animals and their products. FMD virus 34 
(FMDV) is classified into the genus Aphthovirus within the family Picornaviridae. The genome of 35 
FMDV is composed of a single-stranded positive-sense RNA approximately 8.5 kb nucleotides in 36 
length with a poly (C) sequence at the 5' terminus of this genome, and a poly (A) sequence at the 3' 37 
terminus (Mason et al., 2003). 38 
In Japan, FMD outbreaks occurred in 2000 and 2010; strains O/JPN/2000 and O/JPN/2010 39 
were isolated from cattle during each outbreak, respectively (Sakamoto et al., 2002; Muroga et al., 40 
2012). In the 2000 epidemic, cases were limited to four cattle farms and eradicated by slaughter of 41 
740 cattle (Sugiura et al., 2001). Typical clinical signs were confirmed only in pigs following 42 
experimental infections with O/JPN/2000; inoculated Japanese Black cattle showed only mild 43 
clinical signs, and Holstein cattle and goats did not demonstrate clinical signs of infection, nor viral 44 
shedding (Yamakawa et al., 2002). In contrast, the FMD outbreak in 2010 spread to 292 farms and 45 
inoculated pigs, Holstein cattle and goats showed clinical signs and significant viral shedding 46 
following experimental infections with O/JPN/2010 (Fukai et al., 2011; Onozato et al., 2014). These 47 
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differences in infectivity and pathogenicity were suspected to contribute to the relative severity of 48 
the 2010 outbreak compared to the one in 2000; however, the molecular mechanisms underlying the 49 
pathogenicity of O/JPN/2000 and O/JPN/2010 are not well understood.  50 
To date, infectious cDNA clones have been constructed for the purposes of understanding viral 51 
replication and pathogenicity at the molecular level as well as for vaccine development (Zibert et al., 52 
1990; Rieder et al., 1993; Garcia-Arriaza et al., 2004; Liu et al., 2004; van Rensburg et al., 2004; 53 
Hema et al., 2009; Xin et al., 2009; Rajasekhar et al., 2013) and recombinant and site-directed 54 
mutants have been used for genomic studies (Falk et al., 1992; Piccone et al., 1995; Ellard et al., 55 
1999; Beard and Mason, 2000; Pacheco et al., 2003; Botner et al., 2011;Seago et al., 2013; Xin et al., 56 
2014). In the present study, a full-length infectious cDNA clone of O/JPN/2010 (pSVL-f02) was 57 
constructed and the recovered virus was compared to its parental strain by in vitro characterization 58 
and experimental infection of pigs.  59 
The FMDV used in this experiment (O/JPN/2010 290-1E) was isolated from the epithelial tissue 60 
of diseased cattle from a farm, which was confirmed as the 235th affected premises of 292 in total 61 
during the 2010 epidemic in Japan. Viral RNA of O/JPN/2010 290-1E was extracted using a High 62 
Pure Viral RNA Kit (Roche Diagnostics, Tokyo, Japan). First-strand cDNA synthesis was performed 63 
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using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics) and random hexamer 64 
primers. Polymerase chain reaction (PCR) was performed using Platinum Taq Polymerase High 65 
Fidelity (Life Technologies, Tokyo, Japan), using primers which were designed based on the 66 
sequence of the O/JPN/2010 290-1E isolate (GenBank accession number LC036265) or other 67 
reports (Sup. Table 1). The PCR fragments were inserted into the pGEM-T Easy cloning vector 68 
(Promega, Tokyo, Japan). The full-length cDNA was assembled with five cDNA clones covering the 69 
complete genome of O/JPN/2010 290-1E using appropriate restriction enzymes and cloned 70 
downstream of the SV40 late promoter in the pSVL vector (formerly Pharmacia Biotech, WI, USA) 71 
(Fig. 1). The 5N-2 clone had a poly (C)18 tract and the 3R-L4 had a poly (A)27 tail confirmed by 72 
sequencing. 73 
African green monkey kidney cell line Cos-7 and porcine kidney cell line IBRS-2 were grown 74 
in Minimum Essential Medium (MEM) (Nissui Pharmaceutical, Tokyo, Japan) in a 12 well culture 75 
plate. At 70–90% confluency, the cells were transfected with 0.1–1000 ng of pSVL-f02 using 76 
Lipofectamine 3000 (Life Technologies) and incubated at 37°C, in 5% CO2. In Cos-7 and IBRS-2 77 
monolayers transfected with 1000 ng of pSVL-f02 DNA, distinct cytopathic effect (CPE) was 78 
observed as soon as 1 day following transfection. At other doses, weak CPE were observed at 1 day 79 
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post-transfection in both cell types transfected with 100 ng of pSVL-f02, but not in cells transfected 80 
with 0.1-10 ng construct up to 3 days post-transfection. The supernatants and cells were collected at 81 
3 days post-transfection, and virus was titrated in porcine kidney cell line, LFBK-alphavbeta6 82 
(LaRocco et al., 2013); at least 100 ng and 10 ng of the plasmid were necessary to produce 83 
infectious virus in Cos-7 and IBRS-2 cells, respectively (Sup. Table 2A). After transfection using 84 
1000 ng of pSVL-f02, supernatant or supernatant and cells were subjected to three freeze/thaw 85 
cycles, clarified and collected at 1 to 3 days post-transfection. The viral titers of these samples were 86 
determined as 50% tissue culture infectious dose (TCID50) in LFBK-αvβ6 cells. The highest titers 87 
were detected at 2 and 1 day(s) post-transfection in Cos-7 and IBRS-2 cells, respectively (Sup. Table 88 
2B). 89 
 The infectious virus from Cos-7 cells was passaged three times on the fetal goat tongue cell 90 
line, ZZR-127 (Brehm et al., 2009), then subsequently on baby hamster kidney cell line, BHK and 91 
ZZR-127 cells to obtain a high titer viral sample (107.3 TCID50/0.1mL) for subsequent studies. The 92 
antigenicity of the recovered virus vSVL-f02 was examined by virus neutralization tests using sera 93 
collected from pigs inoculated with FMDV O/JPN/2010 290-1E isolate (Nos. 1 and 3) or the 94 
recovered virus vSVL-f02 (Nos. 5 and 6) were determined using each virus as an antigen (Sup. Table 95 
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3). There were no remarkable differences between the antibody titers. The antigenicity of the 96 
vSVL-f02 was also examined by an indirect immunofluorescence test using FMDV-specific 97 
monoclonal antibody (MAb) 1H5 which was raised against the O/JPN/2000 strain and reacts with all 98 
seven serotypes of FMDV (Morioka et al., 2009) (Fig. 2). The MAb 1H5 reacted with the recovered 99 
virus vSVL-f02. The plaques of the vSVL-f02 and the parental 290-1E isolate on LFBK and IBRS-2 100 
cell monolayers were visualized by staining with crystal violet, and similar plaque growth was 101 
confirmed (Fig. 3). In addition, vSVL-f02 and the parental 290-1E isolate were inoculated onto 102 
LFBK cell monolayers cultured in 25-cm2 flasks at a multiplicity of infection (MOI) of 2, then the 103 
culture supernatant was harvested at subsequent time points and the amount of virus present was 104 
determined (Fig. 4). Growth curves of both viruses reached a plateau at 12 hours post inoculation 105 
and there were no significant differences in virus titers at each time points of the growth step 106 
calculated by Student’s t-test. Therefore, growth rates of these viruses were not significantly 107 
different, and the in vitro characteristics of the recovered virus vSVL-f02 were demonstrated to be 108 
identical to those of the parental strain 290-1E. 109 
To test pathogenicity, the parental 290-1E isolate or recovered virus vSVL-f02 were inoculated 110 
into pigs. Six 2-month-old pigs were intradermally inoculated with 0.1 ml of 105.0 TCID50 of the 111 
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viruses (group 1: 290-1E, group 2: vSVL-f02) at the right and front heel bulbs. Pigs were observed 112 
for the appearance of clinical signs daily until 14 days post inoculation (dpi). Sera, saliva, and nasal 113 
discharge were collected as described in our previous report (Fukai et al., 2015). Animal 114 
experiments were authorized by the Animal Care and Use Committee of the National Institute of 115 
Animal Health (NIAH) (authorization number: 14-060) and were performed in a high-containment 116 
facility at the NIAH. All pigs infected with either 290-1E isolate or vSVL-f02 developed vesicles by 117 
1 or 2 dpi on their feet, lips, and tongues (Table 1). Viruses were isolated from the sera (1–3 dpi), 118 
saliva (1–6 dpi), and nasal swabs (2–3 dpi) of the 290-1E inoculated pigs, and from the sera (1–3 119 
dpi), saliva (2–5 dpi) and nasal swabs (1–5 dpi) of the vSVL-f02 inoculated pigs by using LFBK 120 
cells. Viral genes were detected in the sera (1–3 dpi), saliva (1–14 dpi) and nasal swabs (2–10 dpi) 121 
collected from 290-1E inoculated pigs, and in the sera (1–8 dpi), saliva (2–14 dpi) and nasal swabs 122 
(1–9 dpi) collected from vSVL-f02 inoculated pigs by reverse transcription PCR (RT-PCR) using the 123 
FM8-9 primer set previously described (Sakamoto et al., 2002). Moreover, virus titers were 124 
determined by the microtitration method using LFBK cells and viral RNA loads were determined by 125 
real-time RT-PCR using primers and a probe described in the Manual of Diagnostic Tests and 126 
Vaccines for Terrestrial Animals 2013 of World Organization for Animal Health. Viral titers in the 127 
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sera, saliva, and nasal swabs collected from pigs in group 1 were 102.1–106.1 TCID50/ml, 102.6–106.3 128 
TCID50/ml and 102.6–106.6 TCID50/ml, respectively, while the viral RNA loads were 106.6–109.8 129 
copies/ml, 107.5–1010.6 copies/ml and 107.7–1010.2 copies/ml (Sup. Tables 4 and 5). In group 2, viral 130 
titers were 102.8–105.3 TCID50/ml, 102.6–105.6 TCID50/ml and 102.6–106.9 TCID50/ml, respectively, 131 
while the viral RNA loads were 106.9–109.5 copies/ml, 107.7–1010.1 copies/ml and 107.4–1010.3 132 
copies/ml (Sup. Tables 4 and 5). Antibodies were detected by liquid-phase blocking enzyme-linked 133 
immuno-sorbent assay (LPBE) (Biological Diagnostic Supplies Limited, Scotland, UK) from 5 or 6 134 
dpi in both groups and the antibodies against non-structural protein (NSP) of FMDV were detected 135 
using the PrioCHECK FMDV NS Antibody ELISA Kit (Life Technologies) from 7 or 8 dpi, and 6–8 136 
dpi in groups 1 and 2, respectively. Therefore, no significant differences in clinical signs, virus 137 
isolation and titers, viral RNA loads and antibody responses were observed between groups 1 and 2.  138 
In the present study, plasmid pSVL-f02 containing a full-length cDNA of FMDV O/JPN/2010 139 
290-1E isolate was constructed and the vSVL-f02 virus was recovered following transfection of 140 
mammalian cells. The pSVL-f02, which is based on pSVL, harbors a full-length FMDV cDNA 141 
within the SV40 VP1 translational unit and carries the SV40 origin of replication. Therefore, the 142 
replication efficiency of this plasmid should theoretically be greatly increased in Cos-7 cells which 143 
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express the SV40 large T antigen and result in high levels of protein expression following DNA 144 
transfection (Mellon et al., 1981). In this study, contrary to expectations, transfection efficiency did 145 
not increase in Cos-7 cells compared to IBRS-2 cells. The reason for this is unknown; however, it 146 
was probably due to the difference in susceptibility to infection with FMDV between Cos-7 and 147 
IBRS-2 cells. 148 
The in vitro characteristics of vSVL-f02, including its antigenicity in the neutralization test, 149 
indirect immunofluorescence, and plaque size and one-step growth, were identical to those of the 150 
parental 290-1E isolate (Fig 2-4, Sup. Table 3). In the animal experiments, pigs inoculated with 151 
either the vSVL-f02 or O/JPN/2010 290-1E isolate developed vesicles on their feet, lips and tongues 152 
beginning at 1 or 2 dpi. In addition, there were no significant differences between groups 1 and 2 in 153 
the dynamics of viral loads in serum, saliva, and nasal swabs or in the development of anti-FMDV 154 
and anti-NSP antibodies (Table 1, Sup. Tables 4 and 5). These data demonstrate that the in vitro and 155 
in vivo characteristics of the virus recovered from pSVL-f02 transfected cells were consistent with 156 
those of parental virus. Therefore, we concluded that a full-length cDNA of FMDV O/JPN/2010 157 
290-1E was successfully cloned and constructed. This infectious cDNA is therefore a valuable tool 158 
to analyze the molecular mechanisms of differences in pathogenicity of O/JPN/2000 and 159 
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O/JPN/2010 strains, as well as to conduct further studies to understand the mechanisms of virus 160 
replication and determinants of pathogenicity of FMDV, and to develop genetically engineered 161 
vaccines.  162 
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Figure Legends 266 
Fig. 1. Construction of full-length cDNA clone of the FMDV O/JPN/2010 290-1E isolate. Five 267 
cDNA clones comprising the genome of the 290-1E isolate were ligated to each other using 268 
appropriate restriction enzymes and inserted into the pSVL plasmid to create a full-length cDNA 269 
identified as pSVL-f02. 270 
Fig. 2. Indirect immunofluorescence test of IBRS-2 cells infected with vSVL-f02. Alexa Fluor 271 
488-conjugated goat anti-mouse IgG (H+L) antibody (Life Technologies) was used for detection. 272 
Coverslips were mounted using ProLong Gold Antifade Reagent with DAPI (Life Technologies). (a) 273 
vSVL-f02, (b) No infection.  274 
Fig. 3. Comparison of plaque size of 290-1E isolate and vSVL-f02. (a) and (c) 290-1E isolate 275 
inoculated onto IBRS-2 or LFBK monolayer cells, respectively, (b) and (d) vSVL-f02 inoculated 276 
onto IBRS-2 or LFBK monolayer cells, respectively. The cultures were fixed 1 day after the 277 
inoculation and stained with crystal violet.  278 
Fig. 4. One-step growth curves of 290-1E isolate and vSVL-f02. The LFBK cell monolayers were 279 
inoculated with each virus at a MOI of 2 and incubated at 37°C. Samples of supernatant were 280 
collected at the indicated times and viral infectivity was determined using a standard plaque assay. 281 
  
Table 1. Isolation of viruses, detection of viral genes, and detection of antibodies in clinical samples obtained from infected pigs 
 
Group Pig 
Virus 
Clinical Days post infection 
No. No. sample 0 1 2 3 4 5 6 7 8 9 10 13/14 
1 1 290-1E Serum -/-a +/+ +/+ +/+ -/- -/- -/- -/- -/- -/- -/- -/- 
   Saliva -/- +/+ +/+ +/+ +/+ -/+ -/+ -/+ -/+ -/+ -/+ -/- 
   Nasal swab -/- -/- +/+ +/+ -/+ -/+ -/+ -/- -/- -/- -/+ -/- 
   LPBEb ＜32	 ＜32	 ＜32	 ＜32	 ＜32	 45 90 181 256 181 362 181 
   NSPc - - - - - - - + + + + + 
 2  Serum -/- +/+ +/+ +/+ -/- -/- -/- -/- -/- -/- -/- -/- 
   Saliva -/- -/- +/+ +/+ +/+ -/+ +/+ -/+ -/+ -/+ -/- -/+ 
   Nasal swab -/- -/- +/+ +/+ -/+ -/+ -/+ -/+ -/+ -/- -/- -/- 
   LPBE ＜32	 ＜32	 ＜32	 ＜32	 ＜32	 ＜32	 45 90 181 181 256 181 
   NSP - - - - - - - + + + + + 
 3  Serum -/- +/+ +/+ +/+ -/- -/- -/- -/- -/- -/- -/- -/- 
   Saliva -/- -/- +/+ +/+ +/+ -/+ -/+ -/+ -/+ -/+ -/+ -/- 
   Nasal swab -/- -/- +/+ +/+ -/+ -/+ -/+ -/+ -/+ -/- -/+ -/- 
   LPBE ＜32	 ＜32	 ＜32	 ＜32	 ＜32	 ＜32	 32 45 90 181 256 362 
   NSP - - - - - - - - + + + + 
2 4 vSVL-f02 Serum -/- +/+ +/+ -/+ -/- -/- -/- -/- -/- -/- -/- -/- 
  
   
Saliva -/- -/- +/+ +/+ -/+ -/+ -/+ -/- -/+ -/+ -/- -/- 
   Nasal swab -/- -/- +/+ +/+ -/+ -/+ -/+ -/+ -/+ -/+ -/- -/- 
   LPBE ＜32	 ＜32	 ＜32	 ＜32	 ＜32	 ＜32	 45 90 90 90 90 181 
   NSP - - - - - - - - + + + + 
 5  Serum -/- +/+ +/+ +/+ -/- -/- -/- -/- -/- -/- -/- -/- 
   Saliva -/- -/- +/+ +/+ +/+ +/+ -/+ -/+ -/+ -/+ -/+ -/- 
   Nasal swab -/- +/+ +/+ +/+ +/+ +/+ -/+ -/+ -/+ -/- -/- -/- 
   LPBE ＜32	 ＜32	 ＜32	 ＜32	 ＜32	 32 45 90 181 181 181 256 
   NSP - - - - - - - + + + + + 
 6  Serum -/- +/+ +/+ +/+ -/- -/- -/- -/+ -/+ -/- -/- -/- 
   Saliva -/- -/- +/+ +/+ +/+ -/+ -/+ -/+ -/- -/+ -/- -/+ 
   Nasal swab -/- -/- +/+ +/+ +/+ -/+ -/+ -/+ -/+ -/- -/- -/- 
   LPBE ＜32	 ＜32	 ＜32	 ＜32	 ＜32	 64 181 362 362 256 181 256 
      NSP - - - - - - + + + + + + 
 
Boxes in the table indicate the day at which obvious vesicles appeared in each pig. 
a Isolation of virus/detection of virus gene. 
b Antibodies against foot-and-mouth disease virus (FMDV) were detected and titrated by liquid-phase blocking enzyme-linked immuno-sorbent assay (LPBE). 
c Antibodies against non-structural protein (NSP) of FMDV were detected using the PrioCHECK FMDV NS Antibody ELISA Kit.  
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